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Multi-ancestry study of blood lipid levels identiﬁes
four loci interacting with physical activity
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Many genetic loci affect circulating lipid levels, but it remains unknown whether lifestyle
factors, such as physical activity, modify these genetic effects. To identify lipid loci interacting
with physical activity, we performed genome-wide analyses of circulating HDL cholesterol,
LDL cholesterol, and triglyceride levels in up to 120,979 individuals of European, African,
Asian, Hispanic, and Brazilian ancestry, with follow-up of suggestive associations in an
additional 131,012 individuals. We ﬁnd four loci, in/near CLASP1, LHX1, SNTA1, and CNTNAP2,
that are associated with circulating lipid levels through interaction with physical activity;
higher levels of physical activity enhance the HDL cholesterol-increasing effects of the
CLASP1, LHX1, and SNTA1 loci and attenuate the LDL cholesterol-increasing effect of the
CNTNAP2 locus. The CLASP1, LHX1, and SNTA1 regions harbor genes linked to muscle function
and lipid metabolism. Our results elucidate the role of physical activity interactions in the
genetic contribution to blood lipid levels.
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C irculating levels of blood lipids are strongly linked to therisk of atherosclerotic cardiovascular disease. Regularphysical activity (PA) improves blood lipid proﬁle by
increasing the levels of high-density lipoprotein cholesterol
(HDL-C) and decreasing the levels of low-density lipoprotein
cholesterol (LDL-C) and triglycerides (TG)1. However, there is
individual variation in the response of blood lipids to PA, and
twin studies suggest that some of this variation may be due to
genetic differences2. The genes responsible for this variability
remain unknown.
More than 500 genetic loci have been found to be associated
with blood levels of HDL-C, LDL-C, or TG in published genome-
wide association studies (GWAS)3–12. At present, it is not known
whether any of these main effect associations are modiﬁed by PA.
Understanding whether the impact of lipid loci can be modiﬁed
by PA is important because it may give additional insight into
biological mechanisms and identify subpopulations in whom PA
is particularly beneﬁcial.
Here, we report results from a genome-wide meta-analysis of
gene–PA interactions on blood lipid levels in up to 120,979 adults
of European, African, Asian, Hispanic, or Brazilian ancestry, with
follow-up of suggestive associations in an additional 131,012
individuals. We show that four loci, in/near CLASP1, LHX1,
SNTA1, and CNTNAP2, are associated with circulating lipid levels
through interaction with PA. None of these four loci have been
identiﬁed in published main effect GWAS of lipid levels. The
CLASP1, LHX1, and SNTA1 regions harbor genes linked to
muscle function and lipid metabolism. Our results elucidate the
role of PA interactions in the genetic contribution to blood lipid
levels.
Results
Genome-wide interaction analyses in up to 250,564 indivi-
duals. We assessed effects of gene–PA interactions on serum
HDL-C, LDL-C, and TG levels in 86 cohorts participating in the
Cohorts for Heart and Aging Research in Genomic Epidemiology
(CHARGE) Gene-Lifestyle Interactions Working Group13. PA
was harmonized across participating studies by categorizing it
into a dichotomous variable. The participants were deﬁned as
inactive if their reported weekly energy expenditure in moderate-
to-vigorous intensity leisure-time or commuting PA was less than
225 metabolic equivalent (MET) minutes per week (corre-
sponding to approximately 1 h of moderate-intensity PA), while
all other participants were deﬁned as physically active (Supple-
mentary Data 1).
The analyses were performed in two stages. Stage 1 consisted of
genome-wide meta-analyses of linear regression results from 42
cohorts, including 120,979 individuals of European [n= 84,902],
African [n= 20,487], Asian [n= 6403], Hispanic [n= 4749], or
Brazilian [n= 4438] ancestry (Supplementary Tables 1 and 2;
Supplementary Data 2; Supplementary Note 1). All variants that
reached two-sided P < 1 × 10−6 in the Stage 1 multi-ancestry
meta-analyses or ancestry-speciﬁc meta-analyses were taken
forward to linear regression analyses in Stage 2, which included
44 cohorts and 131,012 individuals of European [n= 107,617],
African [n= 5384], Asian [n= 6590], or Hispanic [n= 11,421]
ancestry (Supplementary Tables 3 and 4; Supplementary Data 3;
Supplementary Note 2). The summary statistics from Stage 1 and
Stage 2 were subsequently meta-analyzed to identify lipid loci
whose effects are modiﬁed by PA.
We identiﬁed lipid loci interacting with PA by three different
approaches applied to the meta-analysis of Stage 1 and Stage 2:
(i) we screened for genome-wide signiﬁcant SNP × PA-interac-
tion effects (PINT < 5 × 10−8); (ii) we screened for genome-wide
signiﬁcant 2 degree of freedom (2df) joint test of SNP main
effect and SNP × PA interaction14 (PJOINT < 5 × 10−8); and
(iii) we screened all previously known lipid loci3–12 for signiﬁcant
SNP × PA-interaction effects, Bonferroni-correcting for the
number of independent variants tested (r2 < 0.1 within 1 Mb
distance; PINT= 0.05/501= 1.0 × 10−4).
PA modiﬁes the effect of four loci on lipid levels. Three
novel loci (>1Mb distance and r2 < 0.1 with any previously
identiﬁed lipid locus) were identiﬁed: in CLASP1 (rs2862183,
PINT= 8 × 10−9), near LHX1 (rs295849, PINT= 3 × 10−8), and in
SNTA1 (rs141588480, PINT= 2 × 10−8), which showed a genome-
wide signiﬁcant SNP × PA interaction on HDL-C in all ancestries
combined (Table 1, Figs. 1–4). Higher levels of PA enhanced the
HDL cholesterol-increasing effects of the CLASP1, LHX1, and
SNTA1 loci. A novel locus in CNTNAP2 (rs190748049) was
genome-wide signiﬁcant in the joint test of SNP main effect and
SNP × PA interaction (PJOINT= 4 × 10−8) and showed moderate
evidence of SNP × PA interaction (PINT= 2 × 10−6) in the meta-
analysis of LDL-C in all ancestries combined (Table 1, Fig. 5). The
LDL-C-increasing effect of the CNTNAP2 locus was attenuated in
the physically active group as compared to the inactive group.
None of these four loci have been identiﬁed in previous main
effect GWAS of lipid levels.
No interaction between known main effect lipid loci and PA.
Of the previously known 260 main effect loci for HDL-C, 202 for
LDL-C, and 185 for TG3–12, none reached the Bonferroni-
corrected threshold (two-sided PINT= 1.0 × 10−4) for SNP × PA
interaction alone (Supplementary Data 4-6). We also found no
signiﬁcant interaction between a combined score of all published
European-ancestry loci for HDL-C, LDL-C, or TG with PA
(Supplementary Datas 7–9) using our European-ancestry sum-
mary results (two-sided PHDL-C= 0.14, PLDL-C= 0.77, and PTG=
0.86, respectively), suggesting that the beneﬁcial effect of PA on
lipid levels may be independent of genetic risk15.
Potential functional roles of the loci interacting with PA. While
the mechanisms underlying the beneﬁcial effect of PA on circu-
lating lipid levels are not fully understood, it is thought that the
changes in plasma lipid levels are primarily due to an improve-
ment in the ability of skeletal muscle to utilize lipids for energy
due to enhanced enzymatic activities in the muscle16,17. Of the
four loci we found to interact with PA, three, in CLASP1, near
LHX1, and in SNTA1, harbor genes that may play a role in muscle
function18,19 and lipid metabolism20,21.
The lead variant rs2862183 (minor allele frequency (MAF)
22%) in the CLASP1 locus which interacts with PA on HDL-C
levels is an intronic SNP in CLASP1 that encodes a microtubule-
associated protein (Fig. 2). The rs2862183 SNP is associated with
CLASP1 expression in esophagus muscularis (P= 3 × 10−5) and is
in strong linkage disequilibrium (r2 > 0.79) with rs13403769
variant that shows the strongest association with CLASP1
expression in the region (P= 7 × 10−7). Another potent causal
candidate gene in this locus is the nearby GLI2 gene which has
been found to play a role in skeletal myogenesis18 and the
conversion of glucose to lipids in mouse adipose tissue20 by
inhibiting hedgehog signaling.
The rs295849 (MAF 38%) variant near LHX1 interacts with PA
on HDL-C levels. However, the more likely causal candidate gene
in this locus is acetyl-CoA carboxylase (ACACA), which plays a
crucial role in fatty acid metabolism21 (Fig. 3). Rare acetyl-CoA
carboxylase deﬁciency has been linked to hypotonic myopathy,
severe brain damage, and poor growth22.
The lead variant in the SNTA1 locus (rs141588480) interacts
with PA on HDL-C and is an insertion only found in individuals
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of African (MAF 6%) or Hispanic (MAF 1%) ancestry. The
rs141588480 insertion is in the SNTA1 gene that encodes the
syntrophin alpha 1 protein, located at the neuromuscular
junction and altering intracellular calcium ion levels in muscle
tissue (Fig. 4). Snta1-null mice exhibit differences in muscle
regeneration after a cardiotoxin injection19. Two weeks following
the injection into mouse tibialis anterior, the muscle showed
hypertrophy, decreased contractile force, and neuromuscular
junction dysfunction. Furthermore, exercise endurance of the
mice was impaired in the early phase of muscle regeneration19. In
humans, SNTA1 mutations have been linked to the long-QT
syndrome23.
The fourth locus interacting with PA is CNTNAP2, with the
lead variant (rs190748049) intronic and no other genes nearby
(Fig. 5). The rs190748049 variant is most common in African-
ancestry (MAF 8%), less frequent in European-ancestry (MAF
2%), and absent in Asian- and Hispanic-ancestry populations.
The protein coded by the CNTNAP2 gene, contactin-associated
protein like-2, is a member of the neurexin protein family. The
protein is located at the juxtaparanodes of myelinated axons
where it may have an important role in the differentiation of the
axon into speciﬁc functional subdomains. Mice with a Cntnap2
knockout are used as an animal model of autism and show altered
phasic inhibition and a decreased number of interneurons24.
Human CNTNAP2 variants have been associated with risk of
autism and related behavioral disorders25.
Joint test of SNP main effect and SNP × PA interaction. We
found 101 additional loci that reached genome-wide signiﬁcance
in the 2df joint test of SNP main effect and SNP × PA interaction
on HDL-C, LDL-C, or TG. However, none of these loci showed
evidence of SNP × PA interaction (PINT > 0.001) (Supplementary
Data 10). All 101 main effect-driven loci have been identiﬁed in
previous GWAS of lipid levels3–12.
Discussion
In this genome-wide study of up to 250,564 adults from diverse
ancestries, we found evidence of interaction with PA for four loci,
in/near CLASP1, LHX1, SNTA1, and CNTNAP2. Higher levels of
PA enhanced the HDL cholesterol-increasing effects of CLASP1,
LHX1, and SNTA1 loci and attenuated the LDL cholesterol-
increasing effect of the CNTNAP2 locus. None of these four loci
have been identiﬁed in previous main effect GWAS for lipid
levels3–12.
The loci in/near CLASP1, LHX1, and SNTA1 harbor genes
linked to muscle function18,19 and lipid metabolism20,21. More
speciﬁcally, the GLI2 gene within the CLASP1 locus has been
found to play a role in myogenesis18 as well as in the conversion
of glucose to lipids in adipose tissue20; the ACACA gene within
the LHX1 locus plays a crucial role in fatty acid metabolism21 and
has been connected to hypotonic myopathy22; and the SNTA1
gene is linked to muscle regeneration19. These functions may
relate to differences in the ability of skeletal muscle to use lipids as
an energy source, which may modify the beneﬁcial impact of PA
on blood lipid levels16,17.
The inclusion of diverse ancestries in the present meta-analyses
allowed us to identify two loci that would have been missed in
meta-analyses of European-ancestry individuals alone. In parti-
cular, the lead variant (rs141588480) in the SNTA1 locus is only
polymorphic in African and Hispanic ancestries, and the lead
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Fig. 1 Genome-wide results for interaction with physical activity on HDL cholesterol levels. The P values are two-sided and were obtained by a meta-analysis
of linear regression model results (n up to 250,564). Three loci, in/near CLASP1, LHX1, and SNTA1, reached genome-wide signiﬁcance (P < 5 × 10−8) as
indicated in the plot
Table 1 Lipid loci identiﬁed through interaction with physical activity (PINT < 5 × 10−8) or through joint test for SNP main effect
and SNP × physical activity interaction (PJOINT < 5 × 10−8)
Trait SNP Chr:Pos Gene EA/OA EAF N inactive N active BetaINT seINT PINT PJOINT
Loci identiﬁed through interaction with physical activity
HDL-C rs2862183 2:122415398 CLASP1 T/C 0.22 76,674 154,118 0.014 0.003 7.5E−9 3.6E−7
HDL-C rs295849 17:35161748 LHX1 T/G 0.38 78,288 160,924 0.009 0.002 2.7E−8 6.8E−7
HDL-C rs141588480 20:32013913 SNTA1 Ins/Del 0.95 8,694 18,585 0.054 0.010 2.0E−8 6.1E−7
Loci identiﬁed through joint test for SNP main effect and SNP × physical activity interaction
LDL-C rs190748049 7:146418260 CNTNAP2 C/T 0.95 14,912 28,715 −7.2 1.5 1.6E−6 4.2E−8
All loci were identiﬁed in the meta-analyses of all ancestries combined. HDL-C was natural logarithmically transformed, whereas LDL-C was not transformed. The P values are two-sided and were
obtained using a meta-analysis of linear regression model results. EA effect allele, EAF effect allele frequency, OA other allele, betaINT effect size for interaction with physical activity (=the change in
logarithmically transformed HDL-C or untransformed LDL-C levels in the active group as compared to the inactive group per each effect allele), seINT standard error for interaction with physical activity
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variant (rs190748049) in the CNTNAP2 locus is four times more
frequent in African-ancestry than in European-ancestry. Our
ﬁndings highlight the importance of multi-ancestry investigations
of gene-lifestyle interactions to identify novel loci.
We did not ﬁnd additional novel loci when jointly testing for
SNP main effect and interaction with PA. While 101 loci reached
genome-wide signiﬁcance in the joint test on HDL-C, LDL-C, or
TG, all of these loci have been identiﬁed in previous GWAS of
lipid levels3–12, and none of them showed evidence of SNP × PA
interaction. The 2df joint test bolsters the power to detect novel
loci when both main and an interaction effect are present14. The
lack of novel loci identiﬁed by the 2df test suggests that the loci
Asian (n = 4209)
Brazilian (n = 4438)
African (n = 20,118)
Hispanic (n = 4308)
Hispanic (n = 11,421)
African (n = 5384)
European (n = 100,936)
Asian (n = 4732)
European (n = 83,666)
Stage 2: P = 0.013
l2=0%, n = 122,473
Stage 1: P = 1.3E–7
l2=42%, n = 116,739
Stage 1+2: P = 2.3E–8
l2=0%, n = 239,212
–0.06 –0.04 –0.02 0.02 0.04 0.06 34.5
10
8
6
4
2
0
TAF15 CCL3L3
CCL3L1
TBC1D3H
CCL4L1
CCL4L2
LOC101060321
TBCD3F
TBC1D3B
MRM1
DHRS11
GGNBP2
LHX1
AATF
MIR2909
ACACA SYNRG
DDX52
HNF1B
C17orf78
TADA2A
DUSP14
MIR378J
PIGW
MYO19
ZNHIT3
HEATR9
CCL5 CCL4
RDM1
LYZL6
CCL16
CCL14
CCL15–CCL14
CCL15
CCL23
35 35.5 36
Position on chr17 (Mb)
0
Beta (mg/dL per G allele)
Locus near LHX1
100
80
60
40
20
R
ec
om
bi
na
tio
n 
ra
te
 (c
M/
Mb
)
0
rs295849
0.2
0.4
0.6
0.8
r 2
–
lo
g 1
0 
(p
-
va
lu
e)
a b
Fig. 3 Interaction of rs295849 near LHX1 with physical activity on HDL cholesterol levels. The beta and 95% conﬁdence intervals in the forest plot (a) is
shown for the rs295849 × physical activity interaction term, i.e., it indicates the increase in logarithmically transformed HDL cholesterol levels in the active
group as compared to the inactive group per each G allele of rs295849. The −log10 (P value) in the association plot (b) is also shown for the rs295849 ×
physical activity interaction term. The P values are two-sided and were obtained by a meta-analysis of linear regression model results. The ﬁgure was
generated using LocusZoom (http://locuszoom.org)
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Fig. 2 Interaction of rs2862183 in CLASP1 with physical activity on HDL cholesterol levels. The beta and 95% conﬁdence intervals in the forest plot (a) is
shown for the rs2862183 × physical activity interaction term, i.e., it indicates the increase in logarithmically transformed HDL cholesterol levels in the active
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showing the strongest SNP × PA interaction on lipid levels are not
the same loci that show a strong main effect on lipid levels.
In summary, we identiﬁed four loci containing SNPs that
enhance the beneﬁcial effect of PA on lipid levels. The identiﬁ-
cation of the SNTA1 and CNTNAP2 loci interacting with PA was
made possible by the inclusion of diverse ancestries in the ana-
lyses. The gene regions that harbor loci interacting with PA
involve pathways targeting muscle function and lipid metabolism.
Our ﬁndings elucidate the role and underlying mechanisms of PA
interactions in the genetic regulation of blood lipid levels.
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Methods
Study design. The present study collected summary data from 86 participating
cohorts and no individual-level data were exchanged. For each of the participating
cohorts, the appropriate ethics review board approved the data collection and all
participants provided informed consent.
We included men and women 18–80 years of age and of European, African,
Asian, Hispanic, or Brazilian ancestry. The meta-analyses were performed in two
stages13. Stage 1 meta-analyses included 42 studies with a total of 120,979
individuals of European (n= 84,902), African (n= 20,487), Asian (n= 6403),
Hispanic (n= 4749), or Brazilian ancestry (n= 4438) (Supplementary Table 1;
Supplementary Data 2; Supplementary Note 1). Stage 2 meta-analyses included
44 studies with a total of 131,012 individuals of European (n= 107,617), African
(n= 5384), Asian (n= 6590), or Hispanic (n= 11,421) ancestry (Supplementary
Table 3; Supplementary Data 3; Supplementary Note 2). Studies participating in
Stage 1 meta-analyses carried out genome-wide analyses, whereas studies
participating in Stage 2 only performed analyses for 17,711 variants that reached P
< 10−6 in the Stage 1 meta-analyses and were observed in at least two different
Stage 1 studies with a pooled sample size > 4000. The Stage 1 and Stage 2 meta-
analyses were performed in all ancestries combined and in each ancestry separately.
Outcome traits: LDL-C, HDL-C, and TG. The levels of LDL-C were either directly
assayed or derived using the Friedewald equation (if TG ≤ 400 mg dl−1 and fast-
ing ≥ 8 h). We adjusted LDL-C levels for lipid-lowering drug use if statin use was
reported or if unspeciﬁed lipid-lowering drug use was listed after 1994, when statin
use became common. For directly assayed LDL-C, we divided the LDL-C value by
0.7. If LDL-C was derived using the Friedewald equation, we ﬁrst adjusted total
cholesterol for statin use (total cholesterol divided by 0.8) before the usual calcu-
lation. If study samples were from individuals who were nonfasting, we did not
include either TG or calculated LDL-C in the present analyses. The HDL-C and TG
variables were natural log-transformed, while LDL-C was not transformed.
PA variable. The participating studies used a variety of ways to assess and quantify
PA (Supplementary Data 1). To harmonize the PA variable across all participating
studies, we coded a dichotomous variable, inactive vs. active, that could be applied
in a relatively uniform way in all studies, and that would be congruent with
previous ﬁndings on SNP × PA interactions26–28 and the relationship between PA
and disease outcomes29. Inactive individuals were deﬁned as those with <225 MET-
min per week of moderate-to-vigorous leisure-time or commuting PA (n= 84,495;
34% of all participants) (Supplementary Data 1). We considered all other parti-
cipants as physically active. In studies where MET-min per week measures of PA
were not available, we deﬁned inactive individuals as those engaging in ≤1 h/week
of moderate-intensity leisure-time PA or commuting PA. In studies with PA
measures that were not comparable to either MET-min or hours/week of PA, we
deﬁned the inactive group using a percentage cut-off, where individuals in the
lowest 25% of PA levels were deﬁned as inactive and all other individuals as active.
Genotyping and imputation. Genotyping was performed by each participating
study using Illumina or Affymetrix arrays. Imputation was conducted on the
cosmopolitan reference panel from the 1000 Genomes Project Phase I Integrated
Release Version 3 Haplotypes (2010–2011 data freeze, 2012-03-14 haplotypes).
Only autosomal variants were considered. Speciﬁc details of each participating
study’s genotyping platform and imputation software are described in Supple-
mentary Tables 2 and 4.
Quality control. The participating studies excluded variants with MAF < 1%. We
performed QC for all study-speciﬁc results using the EasyQC package in R30. For
each study-speciﬁc results ﬁle, we ﬁltered out genetic variants for which the pro-
duct of minor allele count (MAC) in the inactive and active strata and imputation
quality [min(MACINACTIVE,MACACTIVE) × imputation quality] did not reach 20.
This removed unstable study-speciﬁc results that reﬂected small sample size, low
MAC, or low-imputation quality. In addition, we excluded all variants with
imputation quality measure <0.5. To identify issues with relatedness, we examined
QQ plots and genomic control inﬂation lambdas in each study-speciﬁc results ﬁle
as well as in the meta-analysis results ﬁles. To identify issues with allele frequencies,
we compared the allele frequencies in each study ﬁle against ancestry-speciﬁc allele
frequencies in the 1000 Genomes reference panel. To identify issues with trait
transformation, we plotted the median standard error against the maximal sample
size in each study. The summary statistics for all beta-coefﬁcients, standard errors,
and P values were visually compared to observe discrepancies. Any issues that were
found during the QC were resolved by contacting the analysts from the partici-
pating studies. Additional details about QC in the context of interactions, including
examples, may be found elsewhere13.
Analysis methods. All participating studies used the following model to test for
interaction:
E Y½  ¼ β0 þ βE  PAþ βG  Gþ βINT  G  PAþ βc  C;
where Y is the HDL-C, LDL-C, or TG value, PA is the PA variable with 0 or 1
coding for active or inactive group, and G is the dosage of the imputed genetic
variant coded additively from 0 to 2. The C is the vector of covariates which
included age, sex, study center (for multi-center studies), and genome-wide prin-
cipal components. From this model, the studies provided the estimated genetic
main effect (βG), estimated interaction effect (βGE), and a robust estimate of the
covariance between βG and βGE. Using these estimates, we performed inverse
variance-weighted meta-analyses for the SNP × PA interaction term alone, and 2df
joint meta-analyses of the SNP effect and SNP × PA interaction combined by the
method of Manning et al.14, using the METAL meta-analysis software. We applied
genomic control correction twice in Stage 1, ﬁrst for study-speciﬁc GWAS results
and again for meta-analysis results, whereas genomic control correction was not
applied to the Stage 2 results as interaction testing was only performed at select
variants. We considered a variant that reached two-sided P < 5 × 10−8 in the meta-
analysis for the interaction term alone or in the joint test of SNP main effect and
SNP × PA interaction, either in the ancestry-speciﬁc analyses or in all ancestries
combined, as genome-wide signiﬁcant. The loci were deﬁned as independent if the
distance between the lead variants was >1Mb.
Combined PA-interaction effect of all known lipid loci. To identify all published
SNPs associated with HDL-C, LDL-C, or TG, we extended the previous curated list
of lipid loci by Davis et al.4 by searching PubMed and Google Scholar databases
and screening the GWAS Catalog. After LD pruning by r2 < 0.1 in the 1000
Genomes European-ancestry reference panel, 260 independent loci remained
associated with HDL cholesterol, 202 with LDL cholesterol, and 185 with TG
(Supplementary Datas 7–9). To approximate the combined PA interaction of all
known European-ancestry loci associated with HDL-C, LDL-C, or TG, we calcu-
lated their combined interaction effect as the weighted sum of the individual SNP
coefﬁcients in our genome-wide summary results for European-ancestry. This
approach has been described previously in detail by Dastani et al.31 and incor-
porated in the package “gtx” in R. We did not weigh the loci by their main effect
estimates from the discovery GWAS data.
Examining the functional roles of loci interacting with PA. We examined
published associations of the identiﬁed lipid loci with other complex traits in
genome-wide association studies by using the GWAS Catalog of the European
Bioinformatics Institute and the National Human Genome Research Institute. We
extracted all published genetic associations with r2 > 0.5 and distance < 500 kb from
the identiﬁed lipid-associated lead SNPs32. We also studied the cis-associations of
the lead SNPs with all genes within ±1Mb distance using the GTEx portal33. We
excluded ﬁndings where our lead SNP was not in strong LD (r2 > 0.5) with the peak
SNP associated with the same gene transcript.
Data availability
The meta-analysis summary results are available for download on the CHARGE
dbGaP website under accession phs000930.
Received: 6 June 2018 Accepted: 7 December 2018
References
1. Leon, A. S. & Sanchez, O. A. Response of blood lipids to exercise training
alone or combined with dietary intervention. Med. Sci. Sports Exerc. 33,
S502–S515 (2001). discussion S528-529.
2. Lakka, H. M., Tremblay, A., Despres, J. P. & Bouchard, C. Effects of long-term
negative energy balance with exercise on plasma lipid and lipoprotein levels in
identical twins. Atherosclerosis 172, 127–133 (2004).
3. Below, J. E. et al. Meta-analysis of lipid-traits in Hispanics identiﬁes novel loci,
population-speciﬁc effects, and tissue-speciﬁc enrichment of eQTLs. Sci. Rep.
6, 19429 (2016).
4. Davis, J. P. et al. Common, low-frequency, and rare genetic variants associated
with lipoprotein subclasses and triglyceride measures in Finnish men from the
METSIM study. PLoS. Genet. 13, e1007079 (2017).
5. Kanai, M. et al. Genetic analysis of quantitative traits in the Japanese
population links cell types to complex human diseases. Nat. Genet. 50,
390–400 (2018).
6. Liu, D. J. et al. Exome-wide association study of plasma lipids in >300,000
individuals. Nat. Genet. 49, 1758–1766 (2017).
7. Lu, X. et al. Genetic susceptibility to lipid levels and lipid change over time and
risk of incident hyperlipidemia in Chinese populations. Circ. Cardiovasc.
Genet. 9, 37–44 (2016).
8. Lu, X. et al. Exome chip meta-analysis identiﬁes novel loci and East Asian-
speciﬁc coding variants that contribute to lipid levels and coronary artery
disease. Nat. Genet. 49, 1722–1730 (2017).
9. Nagy, R. et al. Exploration of haplotype research consortium imputation for
genome-wide association studies in 20,032 Generation Scotland participants.
Genome Med. 9, 23 (2017).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08008-w
6 NATURE COMMUNICATIONS |          (2019) 10:376 | https://doi.org/10.1038/s41467-018-08008-w |www.nature.com/naturecommunications
10. Southam, L. et al. Whole genome sequencing and imputation in isolated
populations identify genetic associations with medically-relevant complex
traits. Nat. Commun. 8, 15606 (2017).
11. Spracklen, C. N. et al. Association analyses of East Asian individuals and
trans-ancestry analyses with European individuals reveal new loci associated
with cholesterol and triglyceride levels. Hum. Mol. Genet. 26, 1770–1784
(2017).
12. van Leeuwen, E. M. et al. Meta-analysis of 49,549 individuals imputed with the
1000 Genomes Project reveals an exonic damaging variant in ANGPTL4
determining fasting TG levels. J. Med. Genet. 53, 441–449 (2016).
13. Rao, D. C. et al. Multiancestry study of gene-lifestyle interactions for
cardiovascular traits in 610 475 individuals from 124 cohorts: design and
rationale. Circ. Cardiovasc. Genet. 10, e001649 (2017).
14. Manning, A. K. et al. Meta-analysis of gene-environment interaction: joint
estimation of SNP and SNP x environment regression coefﬁcients. Genet.
Epidemiol. 35, 11–18 (2011).
15. Khera, A. V. et al. Genetic risk, adherence to a healthy lifestyle, and coronary
disease. N. Engl. J. Med. 375, 2349–2358 (2016).
16. Harrison, M. et al. Lipoprotein particle distribution and skeletal muscle
lipoprotein lipase activity after acute exercise. Lipids Health Dis. 11, 64 (2012).
17. Riedl, I. et al. Regulation of skeletal muscle transcriptome in elderly men after
6 weeks of endurance training at lactate threshold intensity. Exp. Gerontol. 45,
896–903 (2010).
18. McDermott, A. et al. Gli2 and Gli3 have redundant and context-dependent
function in skeletal muscle formation. Development 132, 345–357 (2005).
19. Hosaka, Y. et al. Alpha1-syntrophin-deﬁcient skeletal muscle exhibits
hypertrophy and aberrant formation of neuromuscular junctions during
regeneration. J. Cell Biol. 158, 1097–1107 (2002).
20. Shi, Y. & Long, F. Hedgehog signaling via Gli2 prevents obesity induced by
high-fat diet in adult mice. Elife 6, e31649 (2017).
21. Tong, L. Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and
attractive target for drug discovery. Cell. Mol. Life Sci. 62, 1784–1803
(2005).
22. Blom, W., de Muinck Keizer, S. M. & Scholte, H. R. Acetyl-CoA carboxylase
deﬁciency: an inborn error of de novo fatty acid synthesis. N. Engl. J. Med.
305, 465–466 (1981).
23. Wu, G. et al. Alpha-1-syntrophin mutation and the long-QT syndrome: a
disease of sodium channel disruption. Circ. Arrhythm. Electrophysiol. 1,
193–201 (2008).
24. Bridi, M. S., Park, S. M. & Huang, S. Developmental disruption of GABAAR-
meditated inhibition in Cntnap2 KO mice. eNeuro 4, e0162-17.2017 (2017).
25. Penagarikano, O. & Geschwind, D. H. What does CNTNAP2 reveal about
autism spectrum disorder? Trends Mol. Med. 18, 156–163 (2012).
26. Andreasen, C. H. et al. Low physical activity accentuates the effect of the FTO
rs9939609 polymorphism on body fat accumulation. Diabetes 57, 95–101
(2008).
27. Li, S. et al. Physical activity attenuates the genetic predisposition to obesity in
20,000 men and women from EPIC-Norfolk prospective population study.
PLoS Med. 7, e1000332 (2010).
28. Vimaleswaran, K. S. et al. Physical activity attenuates the body mass index-
increasing inﬂuence of genetic variation in the FTO gene. Am. J. Clin. Nutr.
90, 425–428 (2009).
29. Ekelund, U. et al. Physical activity and all-cause mortality across levels of
overall and abdominal adiposity in European men and women: the European
Prospective Investigation into Cancer and Nutrition Study (EPIC). Am. J.
Clin. Nutr. 101, 613–621 (2015).
30. Winkler, T. W. et al. Quality control and conduct of genome-wide association
meta-analyses. Nat. Protoc. 9, 1192–1212 (2014).
31. Dastani, Z. et al. Novel loci for adiponectin levels and their inﬂuence on type 2
diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891
individuals. PLoS Genet. 8, e1002607 (2012).
32. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait
associations. Nucleic Acids Res. 42, D1001–D1006 (2014).
33. Battle, A., Brown, C. D., Engelhardt, B. E. & Montgomery, S. B. Genetic effects
on gene expression across human tissues. Nature 550, 204–213 (2017).
Acknowledgments
The present work was largely supported by a grant from the US National Heart, Lung,
and Blood Institute (NHLBI) of the National Institutes of Health (R01HL118305). The
full list of acknowledgments appears in the Supplementary Notes 3 and 4.
Author contributions
T.O.K., K. Schwander., D.C.R., and R.J.F.L. conceived and designed the study. The
members of the writing group were T.O.K., A.R.B., R.N., Y.J.S., K.Schwander.,
T. Winkler, H.J., D.I.C., A. Manning., I.N., B.M.P., K.R., P.B.M., M.F., L.A.C., C.N.R., A.
C.M., D.C.R., and R.J.F.L. The genome-wide association results were provided by A.R.B.,
R.N., Y.J.S., K.Strauch, T. Winkler, D.I.C., A. Manning., I.N., H.A., M.R.B., L.d.l.F., N.F.,
X.G., D.V., S.A., M.F.F., M.K., S.K.M., M. Richard, H.W., Z.W., T.M.B., L.F.B., A.C., R.D.,
V.F., F.P.H., A.R.V.R.H., C. Li, K.K.L., J.M., X.S., A.V.S., S.M.T., M. Alver., M. Amini, M.
Boissel, J.F.C., X.C., J. Divers, E.E., C. Gao, M. Graff, S.E.H., M.H., F.C.H., A.U.J., J.H.Z.,
A.T.K., B.K., F.L., L.P.L., I.M.N., R. Rauramaa., M. Riaz, A.R., R. Rueedi, H.M.S., F.T., P.J.
v.d.M., T.V.V., N.V., E.B.W., W.W., X.L., L.R.Y., N.A., D.K.A., E.B., M. Brumat, B.C.,
M.C., Y.D.I.C., M.P.C., J.C., R.d.M., H.J.d.S., P.S.d.V., A.D., J. Ding, C.B.E., J.D.F., Y.F.,
K.P.G., M. Ghanbari, F.G., C.C.G., D.G., T.B.H., J.H., S.H., C.K.H., S.C.H., A.I., J.B.J.,
W.P.K., P.K., J.E.K., S.B.K., Z.K., J.K., C.D.L., C. Langenberg, L.J.L., K.L., R.N.L., C.E.L.,
J. Liang, J. Liu, R.M., A. Manichaikul, T.M., A. Metspalu, Y.M., K.L.M., T.H.M., A.D.M.,
M.A.N., E.E.K.N., C.P.N., S.N., J.M.N., J.O., N.D.P., G.J.P., R.P., N.L.P., A. Peters, P.A.P.,
O.P., D.J.P., A. Poveda, O.T.R., S.S.R., N.R., J.G.R., L.M.R., I.R., P.J.S., R.A.S., S.S.S., M.S.,
J.A.S., H.S., T.S., J.M.S., B.S., K.St., H.T., K.D.T., M.Y.T., J.T., A.G.U., M.Y.v.d.E., D.v.H.,
T.V., M.W., P.W., G.W., Y.B.X., J.Y., C.Y., J.M.Y., W. Zhao, A.B.Z., D.M.B., M. Boehnke,
D.W.B., U.d.F., I.J.D., P.E., T.E., B.I.F., P.F., P.G., C. Gieger, N.K., M.L., T.A.L., T.L.,
P.K.E.M., A.J.O., B.W.J.H.P., N.J.S., X.O.S., P.v.d.H., J.V.V.V.O., P.V., L.E.W., Y.X.W.,
N.J.W., D.R.W., T. Wu, W. Zheng, X.Z., M.K.E., P.W.F., V.G., C.H., B.L.H., T.N.K., Y.L.,
K.E.N., A.C.P., P.M.R., E.S.T., R.M.v.D., E.R.F., S.L.R.K., C.T.L., D.O.M.K., M.A.P., S.R.,
C.M.v.D., J.I.R., C.B.K., W.J.G., B.M.P., K.R., P.B.M., M.F., L.A.C., C.N.R., A.C.M.,
D.C.R., and R.J.F.L.; The meta-analyses were performed by T.O.K. and H.J.; The com-
bined physical activity interaction effects of all known lipid loci were examined by T.O.K.
and H.J.; T.O.K. and C.V.N. collected look-up information in GWAS studies for other
traits; T.O.K. and C.V.N. carried out the eQTL look-ups. All authors reviewed and
approved the ﬁnal manuscript.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
018-08008-w.
Competing interests: Bruce M. Psaty serves on the DSMB of a clinical trial funded by the
manufacturer (Zoll LifeCor) and on the Steering Committee of the Yale Open Data
Access Project funded by Johnson & Johnson. Brenda W.J.H. Penninx has received
research funding (nonrelated to the work reported here) from Jansen Research and
Boehringer Ingelheim. Mike A. Nalls’ participation is supported by a consulting contract
between Data Tecnica International and the National Institute on Aging, National
Institutes of Health, Bethesda, MD, USA. Dr. Nalls also consults for Illumina Inc, the
Michael J. Fox Foundation and University of California Healthcare among others, and
has a Commercial afﬁliation with Data Technica International, Glen Echo, MD, USA.
Jost B. Jonas serves as a consultant for Mundipharma Co. (Cambridge, UK), patent
holder with Biocompatibles UK Ltd. (Franham, Surrey, UK) (Title: Treatment of eye
diseases using encapsulated cells encoding and secreting neuroprotective factor and/or
anti-angiogenic factor; Patent number: 20120263794), and is patent applicant with
University of Heidelberg (Heidelberg, Germany) (Title: Agents for use in the therapeutic
or prophylactic treatment of myopia or hyperopia; Europäische Patentanmeldung 15,000
771.4). Paul W. Franks has been a paid consultant in the design of a personalized
Nutrition trial (PREDICT) as part of a private-public partnership at Kings College
London, UK, and has received research support from several pharmaceutical Companies
as part of European Union Innovative Medicines Initiative (IMI) Projects. Terho
Lehtimäki is employed by Fimlab Ltd. Ozren Polasek is employed by Gen-info
Ltd. The remaining authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Journal peer review information: Nature Communications thanks David Meyre and the
other anonymous Reviewers for their contribution to the peer review of this work. Peer
reviewer reports are available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08008-w ARTICLE
NATURE COMMUNICATIONS |          (2019) 10:376 | https://doi.org/10.1038/s41467-018-08008-w |www.nature.com/naturecommunications 7
Tuomas O. Kilpeläinen1,2, Amy R. Bentley 3, Raymond Noordam4, Yun Ju Sung5, Karen Schwander5,
Thomas W. Winkler6, Hermina Jakupović 1, Daniel I. Chasman7,8, Alisa Manning 9,10, Ioanna Ntalla11,
Hugues Aschard 12,13, Michael R. Brown14, Lisa de las Fuentes 5,15, Nora Franceschini16, Xiuqing Guo17,
Dina Vojinovic18, Stella Aslibekyan19, Mary F. Feitosa20, Minjung Kho21, Solomon K. Musani22,
Melissa Richard 23, Heming Wang24, Zhe Wang14, Traci M. Bartz25, Lawrence F. Bielak21, Archie Campbell26,
Rajkumar Dorajoo27, Virginia Fisher28, Fernando P. Hartwig29,30, Andrea R.V.R. Horimoto31, Changwei Li32,
Kurt K. Lohman33, Jonathan Marten34, Xueling Sim35, Albert V. Smith36,37, Salman M. Tajuddin38, Maris Alver39,
Marzyeh Amini40, Mathilde Boissel41, Jin Fang Chai35, Xu Chen42, Jasmin Divers43, Evangelos Evangelou44,45,
Chuan Gao46, Mariaelisa Graff16, Sarah E. Harris26,47, Meian He48, Fang-Chi Hsu43, Anne U. Jackson49,
Jing Hua Zhao50, Aldi T. Kraja20, Brigitte Kühnel51,52, Federica Laguzzi53, Leo-Pekka Lyytikäinen54,55,
Ilja M. Nolte40, Rainer Rauramaa56, Muhammad Riaz57, Antonietta Robino58, Rico Rueedi59,60,
Heather M. Stringham49, Fumihiko Takeuchi61, Peter J. van der Most40, Tibor V. Varga62, Niek Verweij63,
Erin B. Ware64, Wanqing Wen65, Xiaoyin Li66, Lisa R. Yanek67, Najaf Amin18, Donna K. Arnett68,
Eric Boerwinkle14,69, Marco Brumat70, Brian Cade24, Mickaël Canouil41, Yii-Der Ida Chen17, Maria Pina Concas58,
John Connell71, Renée de Mutsert72, H. Janaka de Silva73, Paul S. de Vries14, Ayşe Demirkan18, Jingzhong Ding74,
Charles B. Eaton75, Jessica D. Faul64, Yechiel Friedlander76, Kelley P. Gabriel77, Mohsen Ghanbari18,78,
Franco Giulianini7, Chi Charles Gu5, Dongfeng Gu79, Tamara B. Harris80, Jiang He81,82, Sami Heikkinen83,84,
Chew-Kiat Heng85,86, Steven C. Hunt87,88, M. Arfan Ikram18,89, Jost B. Jonas90,91, Woon-Puay Koh35,92,
Pirjo Komulainen56, Jose E. Krieger31, Stephen B. Kritchevsky74, Zoltán Kutalik60,93, Johanna Kuusisto84,
Carl D. Langefeld43, Claudia Langenberg50, Lenore J. Launer80, Karin Leander53, Rozenn N. Lemaitre94,
Cora E. Lewis95, Jingjing Liang66, Lifelines Cohort Study, Jianjun Liu27,96, Reedik Mägi39,
Ani Manichaikul97, Thomas Meitinger98,99, Andres Metspalu39, Yuri Milaneschi100, Karen L. Mohlke101,
Thomas H. Mosley Jr.102, Alison D. Murray103, Mike A. Nalls104,105, Ei-Ei Khaing Nang35,
Christopher P. Nelson106,107, Sotoodehnia Nona108, Jill M. Norris109, Chiamaka Vivian Nwuba1,
Jeff O’Connell110,111, Nicholette D. Palmer112, George J. Papanicolau113, Raha Pazoki44, Nancy L. Pedersen42,
Annette Peters52,114, Patricia A. Peyser21, Ozren Polasek115,116,117, David J. Porteous26,47, Alaitz Poveda62,
Olli T. Raitakari118,119, Stephen S. Rich97, Neil Risch120, Jennifer G. Robinson121, Lynda M. Rose7, Igor Rudan122,
Pamela J. Schreiner123, Robert A. Scott50, Stephen S. Sidney124, Mario Sims22, Jennifer A. Smith21,64,
Harold Snieder40, Tamar Sofer10,24, John M. Starr47,125, Barbara Sternfeld124, Konstantin Strauch126,127,
Hua Tang128, Kent D. Taylor17, Michael Y. Tsai129, Jaakko Tuomilehto130,131, André G. Uitterlinden132,
M. Yldau van der Ende63, Diana van Heemst4, Trudy Voortman18, Melanie Waldenberger51,52,
Patrik Wennberg133, Gregory Wilson134, Yong-Bing Xiang135, Jie Yao17, Caizheng Yu48, Jian-Min Yuan136,137,
Wei Zhao21, Alan B. Zonderman138, Diane M. Becker67, Michael Boehnke49, Donald W. Bowden112, Ulf de Faire53,
Ian J. Deary47,139, Paul Elliott44,140, Tõnu Esko39,141, Barry I. Freedman142, Philippe Froguel41,143,
Paolo Gasparini58,70, Christian Gieger51,144, Norihiro Kato61, Markku Laakso84, Timo A. Lakka56,83,145,
Terho Lehtimäki54,55, Patrik K.E. Magnusson42, Albertine J. Oldehinkel146, Brenda W.J.H. Penninx100,
Nilesh J. Samani106,107, Xiao-Ou Shu65, Pim van der Harst63,147,148, Jana V. Van Vliet-Ostaptchouk149,
Peter Vollenweider150, Lynne E. Wagenknecht151, Ya X. Wang91, Nicholas J. Wareham50, David R. Weir64,
Tangchun Wu48, Wei Zheng65, Xiaofeng Zhu66, Michele K. Evans38, Paul W. Franks62,133,152,153,
Vilmundur Gudnason36,154, Caroline Hayward34, Bernardo L. Horta29, Tanika N. Kelly81, Yongmei Liu155,
Kari E. North16, Alexandre C. Pereira31, Paul M. Ridker7,8, E. Shyong Tai35,92,156, Rob M. van Dam35,156,
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08008-w
8 NATURE COMMUNICATIONS |          (2019) 10:376 | https://doi.org/10.1038/s41467-018-08008-w |www.nature.com/naturecommunications
Ervin R. Fox157, Sharon L.R. Kardia21, Ching-Ti Liu 28, Dennis O. Mook-Kanamori72,158, Michael A. Province20,
Susan Redline24, Cornelia M. van Duijn18, Jerome I. Rotter17, Charles B. Kooperberg159, W. James Gauderman160,
Bruce M. Psaty124,161, Kenneth Rice 162, Patricia B. Munroe 11,163, Myriam Fornage23, L. Adrienne Cupples28,164,
Charles N. Rotimi3, Alanna C. Morrison14, Dabeeru C. Rao5 & Ruth J.F. Loos 165,166
1Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen
2200, Denmark. 2Department of Environmental Medicine and Public Health, The Icahn School of Medicine at Mount Sinai, New York 10029 NY,
USA. 3Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda
20892 MD, USA. 4Internal Medicine, Gerontology and Geriatrics, Leiden University Medical Center, Leiden 2300 RC, The Netherlands. 5Division of
Biostatistics, Washington University School of Medicine, St. Louis 63110 MO, USA. 6Department of Genetic Epidemiology, University of
Regensburg, Regensburg 93051, Germany. 7Preventive Medicine, Brigham and Women’s Hospital, Boston 02215 MA, USA. 8Harvard Medical
School, Boston 02131 MA, USA. 9Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston 02114 MA, USA.
10Department of Medicine, Harvard Medical School, Boston 02115 MA, USA. 11Clinical Pharmacology, William Harvey Research Instititute, Barts
and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK. 12Department of Epidemiology,
Harvard School of Public Health, Boston 02115 MA, USA. 13Centre de Bioinformatique, Biostatistique et Biologie Intégrative (C3BI), Institut Pasteur,
Paris 75015, France. 14Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public
Health, The University of Texas Health Science Center at Houston, Houston 77030 TX, USA. 15Cardiovascular Division, Department of Medicine,
Washington University, St. Louis 63110 MO, USA. 16Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill
27514 NC, USA. 17The Institute for Translational Genomics and Population Sciences, Division of Genomic Outcomes, Department of Pediatrics, Los
Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance 90502 CA, USA. 18Department of Epidemiology, Erasmus
University Medical Center, Rotterdam 3015 CE, The Netherlands. 19Department of Epidemiology, University of Alabama at Birmingham,
Birmingham 35294 AL, USA. 20Division of Statistical Genomics, Department of Genetics, Washington University School of Medicine, St. Louis
63108 MO, USA. 21Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor 48109 MI, USA. 22Jackson Heart
Study, Department of Medicine, University of Mississippi Medical Center, Jackson 39213 MS, USA. 23Institute of Molecular Medicine, McGovern
Medical School, University of Texas Health Science Center at Houston, Houston 77030 TX, USA. 24Division of Sleep and Circadian Disorders,
Brigham and Women’s Hospital, Boston 02115 MA, USA. 25Cardiovascular Health Research Unit, Biostatistics and Medicine, University of
Washington, Seattle 98101 WA, USA. 26Centre for Genomic & Experimental Medicine, Institute of Genetics & Molecular Medicine, University of
Edinburgh, Edinburgh EH4 2XU, UK. 27Genome Institute of Singapore, Agency for Science Technology and Research, Singapore 138672, Singapore.
28Biostatistics, Boston University School of Public Health, Boston 02118 MA, USA. 29Postgraduate Program in Epidemiology, Federal University of
Pelotas, Pelotas 96020220 RS, Brazil. 30Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol BS8 2BN, UK.
31Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of São Paulo Medical School, São Paulo 01246903 SP, Brazil.
32Epidemiology and Biostatistics, University of Giorgia at Athens College of Public Health, Athens 30602 GA, USA. 33Public Health Sciences,
Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem 27157 NC, USA. 34Medical Research Council Human Genetics
Unit, Institute of Genetics and Molecular Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK.
35Saw Swee Hock School of Public Health, National University Health System and National University of Singapore, Singapore 117549, Singapore.
36Icelandic Heart Association, 201 Kopavogur, Iceland. 37Department of Biostatistics, University of Michigan, Ann Arbor 48109 MI, USA. 38Health
Disparities Research Section, Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health,
Baltimore 21224 MD, USA. 39Estonian Genome Center, University of Tartu, Tartu 51010, Estonia. 40Department of Epidemiology, University of
Groningen, University Medical Center Groningen, Groningen 9700 RB, The Netherlands. 41CNRS UMR 8199, European Genomic Institute for
Diabetes (EGID), Institut Pasteur de Lille, University of Lille, Lille 59000, France. 42Department of Medical Epidemiology and Biostatistics,
Karolinska Institutet, Stockholm, Stockholm 17177, Sweden. 43Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-
Salem 27157 NC, USA. 44Department of Epidemiology and Biostatistics, Imperial College London, London W2 1PG, UK. 45Department of Hygiene
and Epidemiology, University of Ioannina Medical School, Ioannina 45110, Greece. 46Molecular Genetics and Genomics Program, Wake Forest
School of Medicine, Winston-Salem 27157 NC, USA. 47Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh,
Edinburgh EH8 9JZ, UK. 48Department of Occupational and Environmental Health and State Key Laboratory of Environmental Health for Incubating,
Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China. 49Department of Biostatistics and Center for
Statistical Genetics, University of Michigan, Ann Arbor 48109 MI, USA. 50MRC Epidemiology Unit, University of Cambridge, Cambridge CB2 0QQ,
UK. 51Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg
85764, Germany. 52Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg
85764, Germany. 53Unit of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm 17177, Sweden.
54Department of Clinical Chemistry, Fimlab Laboratories, Tampere 33014, Finland. 55Department of Clinical Chemistry, Finnish Cardiovascular
Research Center—Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere 33014, Finland. 56Foundation for Research in
Health Exercise and Nutrition, Kuopio Research Institute of Exercise Medicine, Kuopio 70100, Finland. 57College of Medicine, Biological Sciences
and Psychology, Health Sciences, The Infant Mortality and Morbidity Studies (TIMMS), Leicester LE1 7RH, UK. 58Institute for Maternal and Child
Health—IRCCS “Burlo Garofolo”, Trieste 34137, Italy. 59Department of Computational Biology, University of Lausanne, Lausanne 1015, Switzerland.
60Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland. 61Department of Gene Diagnostics and Therapeutics, Research Institute, National
Center for Global Health and Medicine, Tokyo 1628655, Japan. 62Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund
University Diabetes Centre, Skåne University Hospital, Malmö 20502, Sweden. 63University of Groningen, University Medical Center Groningen,
Department of Cardiology, Groningen 9700 RB, The Netherlands. 64Survey Research Center, Institute for Social Research, University of Michigan,
Ann Arbor 48104 MI, USA. 65Division of Epidemiology, Department of Medicine, Vanderbilt University School of Medicine, Nashville 37203 TN,
USA. 66Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland 44106 OH, USA. 67Division of
General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore 21287 MD, USA. 68Dean’s Ofﬁce,
University of Kentucky College of Public Health, Lexington 40536 KY, USA. 69Human Genome Sequencing Center, Baylor College of Medicine,
Houston 77030 TX, USA. 70Department of Medical Sciences, University of Trieste, Trieste 34137, Italy. 71Ninewells Hospital & Medical School,
University of Dundee, Dundee DD1 9SY Scotland, UK. 72Clinical Epidemiology, Leiden University Medical Center, Leiden 2300 RC, Netherlands.
73Department of Medicine, Faculty of Medicine, University of Kelaniya, Ragama 11600, Sri Lanka. 74Department of Internal Medicine, Section on
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08008-w ARTICLE
NATURE COMMUNICATIONS |          (2019) 10:376 | https://doi.org/10.1038/s41467-018-08008-w |www.nature.com/naturecommunications 9
Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem 27157 NC, USA. 75Department of Family Medicine and
Epidemiology, Alpert Medical School of Brown University, Providence 02860 RI, USA. 76Braun School of Public Health, Hebrew University-
Hadassah Medical Center, Jerusalem 91120, Israel. 77Department of Epidemiology, Human Genetics & Environmental Sciences, School of Public
Health, The University of Texas Health Science Center at Austin, Austin 78712 TX, USA. 78Department of Genetics, School of Medicine, Mashhad
University of Medical Sciences, Mashhad 91778-99191, Iran. 79Department of Epidemiology, State Key Laboratory of Cardiovascular Disease, Fuwai
Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100006,
China. 80Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health, Bethesda 20892 MD, USA.
81Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans 70112 LA, USA. 82Medicine, Tulane University
School of Medicine, New Orleans 70112 LA, USA. 83Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio Campus
70211, Finland. 84Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio 70210, Finland. 85Department of Paediatrics,
Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore. 86Khoo Teck Puat—National University Children’s
Medical Institute, National University Health System, Singapore 119228, Singapore. 87Division of Epidemiology, Department of Internal Medicine,
University of Utah, Salt Lake City 84132 UT, USA. 88Department of Genetic Medicine, Weill Cornell Medicine, Doha 24144, Qatar. 89Department of
Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam 3015 GD, The Netherlands. 90Department of Ophthalmology,
Medical Faculty Mannheim, University Heidelberg, Mannheim 68167, Germany. 91Beijing Institute of Ophthalmology, Beijing Tongren Eye Center,
Beijing Ophthalmology and Visual Science Key Lab, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. 92Health Services
and Systems Research, Duke-NUS Medical School, Singapore 169857, Singapore. 93Institute of Social and Preventive Medicine, Lausanne University
Hospital, Lausanne 1010, Switzerland. 94Cardiovascular Health Research Unit, Medicine, University of Washington, Seattle 98101 WA, USA.
95Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, School of Medicine, Birmingham 35294 AL,
USA. 96Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore. 97Center
for Public Health Genomics, University of Virginia School of Medicine, Charlottesville 22908 VA, USA. 98Institute of Human Genetics, Helmholtz
Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany. 99Institute of Human Genetics, Technische
Universität München, Munich 80333, Germany. 100Department of Psychiatry, Amsterdam Neuroscience and Amsterdam Public Health Research
Institute, VU University Medical Center, Amsterdam 1081 HV, The Netherlands. 101Department of Genetics, University of North Carolina, Chapel
Hill 27514 NC, USA. 102Geriatrics, Medicine, University of Mississippi, Jackson 39216 MS, USA. 103The Institute of Medical Sciences, Aberdeen
Biomedical Imaging Centre, University of Aberdeen, Aberdeen AB25 2ZD, UK. 104Molecular Genetics Section, Laboratory of Neurogenetics,
National Institute on Aging, Bethesda 20892 MD, USA. 105Data Tecnica International, Glen Echo 20812 MD, USA. 106Department of Cardiovascular
Sciences, University of Leicester, Leicester LE3 9PQ, UK. 107NIHR Leicester Biomedical Research Centre, Glenﬁeld Hospital, Leicester LE3 9QD, UK.
108Cardiovascular Health Research Unit, Division of Cardiology, University of Washington, Seattle 98101 WA, USA. 109Department of Epidemiology,
University of Colorado Denver, Aurora 80045 CO, USA. 110Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of
Medicine, Baltimore 21201 MD, USA. 111Program for Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore
21201 MD, USA. 112Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem 27157 NC, USA. 113Epidemiology Branch,
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda 20892 MD, USA. 114DZHK (German Centre for Cardiovascular
Research), partner site Munich Heart Alliance, Neuherberg 85764, Germany. 115Department of Public Health, Department of Medicine, University
of Split, Split 21000, Croatia. 116Psychiatric Hospital “Sveti Ivan”, Zagreb 10000, Croatia. 117Gen-Info Ltd., 10000 Zagreb, Croatia. 118Department of
Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku 20521, Finland. 119Research Centre of Applied and Preventive
Cardiovascular Medicine, University of Turku, Turku 20520, Finland. 120Institute for Human Genetics, Department of Epidemiology and Biostatistics,
University of California, San Francisco 94143 CA, USA. 121Department of Epidemiology and Medicine, University of Iowa, Iowa City 52242 IA, USA.
122Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh EH16 4UX,
UK. 123Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis 55454 MN, USA. 124Kaiser
Permanente Washington, Health Research Institute, Seattle 98101 WA, USA. 125Alzheimer Scotland Dementia Research Centre, The University of
Edinburgh, Edinburgh EH8 9JZ, UK. 126Institute of Genetic Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental
Health, Neuherberg 85764, Germany. 127Institute of Medical Informatics Biometry and Epidemiology, Ludwig-Maximilians-Universitat Munchen,
Munich 81377, Germany. 128Department of Genetics, Stanford University, Stanford 94305 CA, USA. 129Department of Laboratory Medicine and
Pathology, University of Minnesota, Minneapolis 55455 MN, USA. 130Public Health Solutions, National Institute for Health and Welfare, Helsinki
00271, Finland. 131Diabetes Research Group, King Abdulaziz University, Jeddah 21589, Saudi Arabia. 132Department of Internal Medicine, Erasmus
University Medical Center, Rotterdam 3015 CE, The Netherlands. 133Department of Public Health & Clinical Medicine, Umeå University, Umeå
90185 Västerbotten, Sweden. 134Jackson Heart Study, School of Public Health, Jackson State University, Jackson 39213 MS, USA. 135State Key
Laboratory of Oncogene and Related Genes & Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University
School of Medicine, Shanghai 200000, China. 136Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh,
Pittsburgh 15261 PA, USA. 137Division of Cancer Control and Population Sciences, UPMC Hillman Cancer, University of Pittsburgh, Pittsburgh 15232
PA, USA. 138Behavioral Epidemiology Section, Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes
of Health, Baltimore 21224 MD, USA. 139Psychology, The University of Edinburgh, Edinburgh EH8 9JZ, UK. 140MRC-PHE Centre for Environment
and Health, Imperial College London, London W2 1PG, UK. 141Broad Institute of the Massachusetts Institute of Technology and Harvard University,
Boston 02142 MA, USA. 142Section on Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem 27157 NC,
USA. 143Department of Genomics of Common Disease, Imperial College London, London W12 0NN, UK. 144German Center for Diabetes Research
(DZD e.V.), Neuherberg 85764, Germany. 145Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio 70210,
Finland. 146Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.
147Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen 9700 RB, The Netherlands. 148Durrer Center
for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht 1105 AZ, The Netherlands. 149Department of Endocrinology, University of
Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands. 150Internal Medicine, Department of Medicine, Lausanne
University Hospital, Lausanne 1011, Switzerland. 151Public Health Sciences, Wake Forest School of Medicine, Winston-Salem 27157 NC, USA.
152Harvard T. H. Chan School of Public Health, Department of Nutrition, Harvard University, Boston 02115 MA, USA. 153OCDEM, Radcliffe
Department of Medicine, University of Oxford, Oxford OX3 7LE, UK. 154Faculty of Medicine, University of Iceland, Reykjavik 101, Iceland. 155Public
Health Sciences, Epidemiology and Prevention, Wake Forest University Health Sciences, Winston-Salem 27157 NC, USA. 156Department of
Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore. 157Cardiology, Medicine, University of
Mississippi Medical Center, Jackson 39216 MS, USA. 158Public Health and Primary Care, Leiden University Medical Center, Leiden 2300 RC, The
Netherlands. 159Fred Hutchinson Cancer Research Center, University of Washington School of Public Health, Seattle 98109 WA, USA.
160Biostatistics, Preventive Medicine, University of Southern California, Los Angeles 90032 CA, USA. 161Cardiovascular Health Research Unit,
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08008-w
10 NATURE COMMUNICATIONS |          (2019) 10:376 | https://doi.org/10.1038/s41467-018-08008-w |www.nature.com/naturecommunications
Epidemiology, Medicine and Health Services, University of Washington, Seattle 98101 WA, USA. 162Department of Biostatistics, University of
Washington, Seattle 98105 WA, USA. 163NIHR Barts Cardiovascular Research Centre, Barts and The London School of Medicine and Dentistry,
Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. 164NHLBI Framingham Heart Study, Framingham 01702 MA,
USA. 165Icahn School of Medicine at Mount Sinai, The Charles Bronfman Institute for Personalized Medicine, New York 10029 NY, USA. 166Icahn
School of Medicine at Mount Sinai, The Mindich Child Health and Development Institute, New York 10029 NY, USA
Lifelines Cohort Study
Behrooz Z. Alizadeh40, H. Marike Boezen40, Lude Franke147, Gerjan Navis167, Marianne Rots168,
Morris Swertz147, Bruce H.R. Wolffenbuttel149 & Cisca Wijmenga147
167Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ,
The Netherlands. 168Department of Medical Biology, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The
Netherlands
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08008-w ARTICLE
NATURE COMMUNICATIONS |          (2019) 10:376 | https://doi.org/10.1038/s41467-018-08008-w |www.nature.com/naturecommunications 11
